The Need for Effective Colorectal Cancer Screening: Are New Tests Really Necessary?
Colorectal cancer remains a significant health issue, particularly in countries like Germany, where nearly one in nine cancer diagnoses is related to the colon or rectum. With rising average diagnosis ages—75 for women and 71 for men—early detection is vital. The recent update by the American Cancer Society, introducing two nucleic acid-based stool tests, reignites the debate: do we truly need more screening options, or is there a more fundamental issue at play?
Understanding Colorectal Cancer
The growth of colorectal cancer is typically slow, making early intervention crucial. According to Prof. Michael Hoffmeister from the German Cancer Research Center (DKFZ), effective screening can identify and remove precursors before they develop into cancer. Early-stage cancers may have a cure rate of up to 90%, highlighting the necessity of timely detection.
Current Screening Guidelines in Germany
Under the S3 guidelines for colorectal carcinoma, individuals aged 50 and over can undergo either two colonoscopies at ten-year intervals or an annual stool test to detect occult blood. The fecal immunochemical test (FIT) is most commonly utilized for this purpose.
Both methods have their pros and cons, as Hoffmeister explains. The FIT program is more structured in continuing screening from ages 60 to 75, whereas colonoscopy lacks follow-up tests in older populations. However, colonoscopies are essential for directly identifying and removing cancer precursors, while FIT tests can yield false positives.
New Stool Tests: Are They Worth It?
The newly added nucleic acid-based multitarget stool tests in U.S. guidelines claim to identify colorectal cancer with greater sensitivity. They do this by detecting DNA or RNA fragments from cancer cells, even in non-bleeding lesions. However, Hoffmeister argues these tests aren’t necessarily superior; a standard FIT could enhance sensitivity through adjusted parameters for follow-up colonoscopy.
Moreover, these new tests have lower specificity, leading to more false positives—requiring additional colonoscopies to clarify the source of the blood. Cost is another factor; traditional stool tests run about 20 euros, compared to approximately 500 euros for the new nucleic acid tests. The American Cancer Society has not adequately addressed the implications of these costs for public health.
Focusing on Participation in Screening
One of the more pressing concerns is not the variety of tests available but the participation rate in existing screening options. In Germany, less than 10% of eligible individuals undergo colonoscopies or FIT tests. Efforts by legal health insurance to remind members about screenings every five years have led to slight increases in participation.
Increasing public awareness and reducing barriers to screening are paramount. Hoffmeister emphasizes the need for individuals to choose between colonoscopy and stool testing based on personal preference while strongly recommending participation in at least one of these options.
Conclusion: A Shift Towards Engagement Over Expansion
As healthcare systems continually reassess screening guidelines, the focus should remain on enhancing participation rather than merely introducing new testing modalities. Both colonoscopies and stool tests are effective, but raising awareness and encouraging individuals to take action is ultimately more impactful for reducing colorectal cancer rates.
By prioritizing participation over the expansion of testing options, we can work towards improving early detection and ultimately saving lives.
